A Study of KL590586 in Patients With Advanced Solid Tumors

Inclusion criteria

• ✓. Stage I: locally advanced or metastatic solid tumors that are pathologically diagnosed without standard treatment or intolerant to standard treatments
• ✓. Stage II: locally advanced or metastatic NSCLC, MTC or other solid tumors confirmed by pathology
• ✓. There is at least one measurable target lesion that meets RECIST v1.1 or RANO (only for brain tumor lesions)
• ✓. Age \> or = 18 years old at the time of signing the informed consent form, regardless of gender
• ✓. Within 14 days before the first administration of the study treatment, the Eastern Cooperative Oncology Group (ECOG) performance status score was 0 or 1, and there was no sudden deterioration, and the expected survival time was \> or = 3 months
• ✓. Sufficient organ and bone marrow function (without receiving blood transfusion, erythropoietin, recombinant human thrombopoietin or colony stimulating factor therapy, renal replacement therapy, etc. within 7 days before the examination, the laboratory examination meets the following conditions Regulations): a) Blood routine: absolute neutrophil count (ANC) \> or = 1.0×10\^9/L; platelet count (PLT) \> or = 75×10\^9/L; hemoglobin concentration \> or = 9.0 g/dl; b) Liver function: AST and ALT \< or = 2.5×upper limit of normal (ULN), TBIL\< or = 1.5×ULN; for patients with liver metastasis or primary biliary tract tumors, ALT and AST \< or = 5×ULN; for liver cancer, liver metastasis or Gil Patients with Gilbert's syndrome, TBIL \< or = 3×ULN; c) Renal function: serum creatinine (Cr) \< or = 1.5×ULN or creatinine clearance \> or = 40 ml/min (using the standard Cockcroft-Gault formula); d) Coagulation function: International normalized ratio (INR), activated partial thromboplastin time (APTT) and prothrombin time (PT) \< or = 1.5×ULN;
• ✓. Able to understand and voluntarily sign an informed consent form, and be able to comply with the visit and related procedures stipulated in the plan

Exclusion criteria